Novonesis raised its full-year 2026 organic sales growth outlook to 7%-8% from 5%-7% after delivering 8% growth in the first half, including 9% in the second quarter. Adjusted EBITDA margin reached 37.7% for the first half, and the company expects the full-year margin at the higher end of its 37%-38% range. The Board approved a DKK 2.35 interim dividend per share and an inaugural EUR 1 billion multi-year share buyback, scheduled to begin in the second half of 2026 and expected to finish by the end of 2029, subject to Annual General Meeting authorizations. Most repurchased shares will be cancelled, while a smaller portion will be retained for employee share-based incentive programs. Novo Holdings intends to participate by selling shares and expects to retain approximately 25.5% of Novonesis' share capital after cancellation of repurchased shares. Novonesis also said it had agreed on Aug. 10 to acquire the remaining 77% of MicroBioGen. Shares rose 10.64%, leading the Europe-wide Stoxx 600, after the Copenhagen-listed stock reached a one-year high of 455.50 Danish kroner in early afternoon European trade; the stock was up 12% year to date at the time of the report.